Clinical characteristics, cytokine profiles and plasma IgE in adults with asthma

Objective.It has been reported that organizing pneumonia (OP) develops when patients with rheumatoid arthritis (RA) are treated with biologic disease-modifying antirheumatic drugs (bDMARD). However, the clinical characteristics and pathophysiology of OP in RA remain unknown in patients treated with bDMARD. We investigated the clinical characteristics and cytokine profiles of patients with RA-OP treated with bDMARD or conventional synthetic DMARD (csDMARD).Methods.Twenty-four patients with RA who had developed OP were enrolled. These patients included 12 treated with bDMARD (bDMARD-OP subset) and 12 treated with csDMARD (csDMARD-OP subset). We compared the clinical characteristics and cytokine profiles between the patients with OP (OP subset, n = 24) and non-OP patients (non-OP subset, n = 29).Results.There was no significant difference in clinical characteristics between the OP subset and the non-OP subset. Four patients developed OP within 2 months of bDMARD administration. In the other 8 patients, OP developed more than 1 year after the initiation of bDMARD. OP improved with corticosteroid treatment in all bDMARD-OP patients. After OP improved, bDMARD were readministered in 6 patients, and no OP recurrence was observed in any of these patients. Our multivariate analysis revealed that serum levels of interferon-α (IFN-α), interleukin (IL)-1β, IL-6, IL-8, and interferon-γ–inducible protein 10 were significantly associated with the development of OP, although these cytokines tended to be lower in the bDMARD-OP subset than in the csDMARD-OP subset.Conclusion.OP is unlikely to be fatal in patients treated with bDMARD or csDMARD. IFN-α and proinflammatory cytokines are associated with the pathophysiology of OP in RA.

Download Full-text

Macrolide Resistance, Clinical Features, and Cytokine Profiles in Taiwanese Children with Mycoplasma pneumoniae Infection

Open Forum Infectious Diseases ◽

10.1093/ofid/ofab416 ◽

2021 ◽

Author(s):

Tsung-Hua Wu ◽

Nancy M Wang ◽

Fang-Ching Liu ◽

Hui-Hsien Pan ◽

Fang-Liang Huang ◽

...

Keyword(s):

Respiratory Tract ◽

Mycoplasma Pneumoniae ◽

Clinical Characteristics ◽

Respiratory Tract Infections ◽

Macrolide Resistance ◽

Clinical Severity ◽

Cytokine Profiles ◽

Mlva Type ◽

Tract Infections ◽

Mycoplasma Pneumoniae Infection

Abstract Background The factors to predict the progression of Mycoplasma pneumoniae infection remain inconclusive. Therefore, we investigated macrolide resistance prevalence, M. pneumoniae genotype, and clinical characteristics of childhood M. pneumoniae respiratory tract infections in Taiwan. Methods A total of 295 children hospitalized with respiratory tract infections with positive serological M. pneumoniae immunoglobulin M test results were enrolled in this 3-year prospective study. Oropharyngeal swabs were obtained for M. pneumoniae cultures and PCR tests. All M. pneumoniae specimens were further characterized by P1 typing, multilocus variable-number tandem-repeat analysis (MLVA), and macrolide resistance genotyping. The clinical characteristics and blood cytokine profiles were analyzed accordingly. Results Of 138 M. pneumoniae specimens, type I P1 was the predominant (136/138, 98.6%). MLVA type P (4-4-5-7-2) was the leading strain (42/138, 30.4%), followed by type J, U, A, and X. The overall macrolide-resistant rate was 38.4% (53/138); the resistance rate increased dramatically yearly: 10.6% in 2017, 47.5% in 2018, and 62.5% in 2019 (P < .001). All macrolide-resistant M. pneumoniae (MRMP) harbored the A2063G mutation and were MLVA type 4-5-7-2 (49/53, 92.5%), especially type U and X. No significant differences in clinical symptoms, duration of hospital stay, and radiographic findings were identified among patients between MRMP and macrolide-sensitive M. pneumoniae (MSMP) groups. Patients with MRMP infection had more febrile days before and during hospitalization; higher IL-13 and IL-33 levels than patients with MSMP infection (P < .005). Conclusions MRMP surged in Taiwan throughout the study period, but macrolide resistance was not a determinant factor of clinical severity.

Download Full-text

Clinical characteristics and cytokine profiles of children with acute lower respiratory tract infections caused by human rhinovirus

PLoS ONE ◽

10.1371/journal.pone.0198624 ◽

2018 ◽

Vol 13 (7) ◽

pp. e0198624 ◽

Cited By ~ 8

Author(s):

Jong Gyun Ahn ◽

Dong Soo Kim ◽

Ki Hwan Kim

Keyword(s):

Respiratory Tract ◽

Lower Respiratory Tract ◽

Clinical Characteristics ◽

Respiratory Tract Infections ◽

Human Rhinovirus ◽

Lower Respiratory Tract Infections ◽

Cytokine Profiles ◽

Tract Infections

Download Full-text

Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome

The American Journal of Gastroenterology ◽

10.1038/ajg.2016.223 ◽

2016 ◽

Vol 111 (8) ◽

pp. 1165-1176 ◽

Cited By ~ 38

Author(s):

Sean M P Bennet ◽

Annikka Polster ◽

Hans Törnblom ◽

Stefan Isaksson ◽

Sandrine Capronnier ◽

...

Keyword(s):

Irritable Bowel Syndrome ◽

Clinical Characteristics ◽

Cytokine Profiles ◽

Irritable Bowel

Download Full-text

Clinical characteristics, outcomes and follow-up of COVID-19 infection in cancer patients

10.21203/rs.3.rs-33276/v1 ◽

2020 ◽

Author(s):

Minghao Fang ◽

Jianmin Ling ◽

Yanqing Wu ◽

Zhaohua Wang ◽

Le Yang

Keyword(s):

Cancer Survivors ◽

Cancer Patients ◽

Clinical Characteristics ◽

Demographic Data ◽

Signs And Symptoms ◽

Rt Pcr ◽

Cytokine Profiles ◽

Tnf Α ◽

Clinical Records

Abstract Purpose: The study is to describe the clinical characteristics, outcomes and follow-up of cancer patients with COVID-19. Methods: Clinical records, demographic data, signs and symptoms, laboratory results, cytokine profiles, chest CT scans, comorbidities, treatments, clinical outcomes, and RT-PCR of SARS-CoV-2 after discharge were retrospectively collected for fifty-six cancer patients with laboratory-confirmed COVID-19 pneumonia who were admitted to Tongji Hospital of Huazhong University of Science and Technology, Wuhan, China, from Feb 1 to Apr 1, 2020. Evidence of cytokine profiles were assessed by testing for the IL1β, IL2R, IL6, IL8, IL10, and TNF - α in the peripheral blood of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infected cancer patients. Results: Of 2143 patients with COVID-19, 56 cancer patients were included. The patients were divided into two groups, as cancer survivors, and cancer non-survivors. 12 (21%) patients with lymphopenia (0.5 [0.3-0.7]) had died during hospital stay. In non-survivors, IL2R, IL6, and IL10 were higher. 3(6.8%) cancer survivors with COVID-19 had positive RT-PCR test results again shortly after discharge. Conclusion: The mortality rate of COVID-19 among cancer patients are considerable. Cancer non-survivors are characterized by more severe lymphopenia and a higher levels of cytokines. Recovered cancer survivors still may be virus carriers.

Download Full-text

Clinical characteristics and cytokine profiles of central‐compartment‐type chronic rhinosinusitis

International Forum of Allergy & Rhinology ◽

10.1002/alr.22759 ◽

2021 ◽

Author(s):

Yi‐Tsen Lin ◽

Chih‐Feng Lin ◽

Chun‐Kang Liao ◽

Bor‐Luen Chiang ◽

Te‐Huei Yeh

Keyword(s):

Chronic Rhinosinusitis ◽

Clinical Characteristics ◽

Central Compartment ◽

Cytokine Profiles

Download Full-text

Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics

AJP Renal Physiology ◽

10.1152/ajprenal.00051.2020 ◽

2020 ◽

Vol 318 (6) ◽

pp. F1391-F1399 ◽

Cited By ~ 1

Author(s):

Yuan-Hong Jiang ◽

Jia-Fong Jhang ◽

Yung-Hsiang Hsu ◽

Han-Chen Ho ◽

Ya-Hui Wu ◽

...

Keyword(s):

Interstitial Cystitis ◽

Clinical Characteristics ◽

Area Under The Curve ◽

Pain Syndrome ◽

Bladder Capacity ◽

Bladder Pain Syndrome ◽

Bladder Pain ◽

Logistic Regression Models ◽

Cytokine Profiles ◽

Diagnostic Values

The objective of the present study was to investigate the diagnostic values of urine cytokines in patients with interstitial cystitis/bladder pain syndrome (IC/BPS) and to identify their correlations with clinical characteristics. Urine samples were collected from 127 patients with IC/BPS [European Society for the Study of Interstitial Cystitis (ESSIC) types 1 and 2] and 28 controls. Commercially available multiplex immunoassays (MILLIPLEX map kits) were used to analyze 31 targeted cytokines. Cytokine levels between patients with IC/BPS and controls were analyzed using ANOVA. Receiver-operating characteristic curves of each cytokine to distinguish IC/BPS from controls were generated for calculation of the area under the curve. Patients with IC/BPS had urine cytokine profiles that differed from those of controls. Between patients with ESSIC type 1 and 2 IC/BPS, urine cytokine profiles were also different. Among cytokines with high diagnostic values (i.e., area under the curve > 0.7) with respect to distinguish patients with ESSIC type 2 IC/BPS from controls, regulated upon activation, normal T cell expressed and presumably secreted (RANTES), macrophage inflammatory protein (MIP)-1β, and IL-8 were of higher sensitivity, whereas macrophage chemoattractant protein (MCP)-1, chemokine (C-X-C motif) ligand 10 (CXCL10), and eotaxin-1 were of higher specificity. In multivariate logistic regression models controlling for age, sex, body mass index, and diabetes mellitus, the urine cytokines with high diagnostic values (MCP-1, RANTES, CXCL10, IL-7, and eotaxin-1) remained statistically significant in differentiating IC/BPS and controls. MCP-1, CXCL10, eotaxin-1, and RANTES were positively correlated with glomerulation grade and negatively correlated with maximal bladder capacity. In conclusion, patients with IC/BPS had urine cytokine profiles that clearly differed from those of controls. Urine cytokines might be useful as biomarkers for diagnosing IC/BPS and mapping its clinical characteristics.

Download Full-text